Research Article
Teng-Chou Chen and Li-Chia
Abstract
Chronic myeloid leukemia (CML) has become a chronic and costly disease, since the launch and long-term use of tyrosine kinase inhibitors, including imatinib. Evidence for imatinib’s cost-effectiveness impact were largely based on preference-based quality of life (QoL) measured from randomized controlled trials, however, little is known aboutthe feasibility of QoL measured as a follow-up indicator in real life. This commentary describes our experiences in exploring the QoL measures and attributes influencing QoL in Taiwanese CML patients who were receiving imatinibtreatment.